Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

TB treatment news

Show

From To
TB treatment
CROI 2015: Trial to evaluate the use of health navigators to link HIV/TB patients to care and treatment fails to show positive results

Patients randomized to the support of a health navigator were not more likely than those who received standard of care to complete tuberculosis treatment or begin antiretroviral therapy within three months of HIV diagnosis, according to the results of a South African randomized trial presented here today.

Published
26 February 2015
From
Science Speaks
TB treatment
TB drug candidate starts Phase 1 trial — first in six years

The enrollment of nearly 50 volunteers in the United States will launch the first randomized clinical trial of a potential  new drug to treat TB in six years, the nonprofit product development partnership TB Alliance announced Wednesday.

Published
20 February 2015
From
Science Speaks
TB treatment
TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients

NC-005 trial tests a novel regimen of bedaquiline (Sirturo), pretomanid (formerly known as PA-824), and pyrazinamide; results could pave the way for a three-month TB treatment.

Published
27 October 2014
From
TB Alliance
TB treatment
Newly identified marker helps predict tuberculosis complications in HIV patients

An NIAID study suggests that the increased frequency of an immune cell called CD14++CD16- monocyte is a strong indicator that a patient with HIV and tuberculosis (TB) may develop immune reconstitution inflammatory syndrome (IRIS).

Published
16 October 2014
From
National Institute of Allergy and Infectious Diseases (NIAID) press release
TB treatment
In HIV/TB coinfection, initiate antiretroviral therapy early

Earlier initiation of antiretroviral therapy (ART) significantly lowered mortality in patients with HIV and tuberculosis (TB) co-infection, despite a higher incidence of immune reconstitution inflammatory syndrome (IRIS), according to data presented at 2014 IDWeek.

Published
16 October 2014
From
Monthly Prescribing Reference (MPR)
TB treatment
What does new drug PaMZ mean for TB and HIV treatment?

The development of PaMZ has been hailed as a breakthrough. But what do the experts think?

Published
02 September 2014
From
The Guardian
Drug-resistant TB
Acquired rifampicin resistance more likely in HIV-coinfected patients

Patients with HIV and tuberculosis were more likely to develop acquired rifampicin resistance when treated with a thrice-weekly tuberculosis treatment compared with patients not coinfected with HIV, according to researchers from the National Institute for Research in Tuberculosis in India. The rate of bacteriologic failure was 4% among patients without HIV. Among patients with HIV, the rates were 9% for those not receiving ART and 5% for those receiving ART.

Published
02 September 2014
From
Healio
Delivery of care
From Rhetoric to Reality: An Analysis of Efforts to Scale Up The Response to TB-HIV

A new research report from ACTION global health shows that joint TB-HIV activities are neglected by HIV programs and overwhelmingly carried out by TB programs, and that global guidelines to address TB-HIV have not been prioritized by leading donors and affected countries.

Published
22 July 2014
From
ACTION
HIV, HCV and TB Pipeline Report

Drugs, diagnostics, vaccines, preventive technologies, research towards a cure, and immune-based and gene therapies in development.

Published
21 July 2014
From
Treatment Action Group & i-Base
Tuberculosis and HIV
Apathy in TB fight: The Economist Intelligence Unit

A new report on tuberculosis calls for raising the profile of TB, fight apathy and lack of compelling ambition in addressing the disease.

Published
04 July 2014
From
Stop TB Partnership
← Prev1...34567...13Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.